ClinicalTrials.gg
RecruitingNCT07031063TEOTLUpdated Jun 26, 2025

Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

A Phase 4 interventional study of DTG/3TC and Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) in HIV Infection, Metabolic Syndrome and Antiretroviral Treatment, sponsored by Instituto Mexicano del Seguro Social. Recruiting at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Instituto Mexicano del Seguro Social · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Planned enrollment
29th of 55
124 · median 126
Started
2025
with 1 other
Phase 4
11 of 55
3 open now
Registered
52nd of 55
by date

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 29th largest by planned enrollment, is one of 2 that started in 2025, is one of 11 in phase 4, and was the 52nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

Background: The primary goal of antiretroviral therapy is to prevent HIV-associated morbidity and mortality. The effectiveness of first-line regimens is supported by a large number of clinical trials; current concerns focus on the long-term adverse effects of antiretrovirals, especially integrase strand transfer inhibitors, as they have been associated with significant weight gain, which may be associated with increased cardiovascular risk.

Objective: To determine the effectiveness, safety, and tolerability of Dolutegravir/Lamivudine (DTG/3TC) compared with Bictegravir/Tenofovir Alafenamide/Emtricitabine (BIC/TAF/FTC) in treatment-naive people living with HIV (PWH). Materials and methods: With prior approval from the Ethics and Scientific Research Committee 3502, an open-label, randomized clinical trial will be conducted at the Infectious Diseases Hospital of the National Medical Center "La Raza" from November 2024 to May 2026. Recently diagnosed PWH with no history of PrEP and/or PeP use, without hospitalization criteria, and without a diagnosis of metabolic syndrome based on ATP-III criteria will be identified. They will be invited to participate in the study and, if they accept, they will sign an informed consent form. They will be randomized to start a BIC/TAF/FTC or DTG/3TC 1:1 regimen. Laboratory studies, vital signs, and somatometry including bioimpedance will be performed at 4, 12, 24, 36, 48, 72, 96, 120, 144 weeks of follow-up; viral load and CD4+ count will be measured at weeks 12, 24, 48, 72, 96, 120, 144 weeks after the start of treatment. Sampling will be non-probabilistic; the distribution will be identified using the Kolmogorov-Smirnoff test, and measures of central tendency and percentages will be expressed. Comparisons will be made using the Mann-Whitney U test. Qualitative data will be analyzed using the x2 or Fisher's exact test. Group analysis will be performed at 12, 24, 48, 96 and 144 weeks using the Wilcoxon test. A P value ≤0.05 with a 95% confidence interval will be considered statistically significant.

Read the detailed description

With prior approval of the protocol by the Local Ethics and Scientific Research Committee 3502, PWH attending the HIV clinic at the Infectious Diseases Hospital who are ART (antiretroviral therapy) naive and meet all the protocol inclusion criteria will be identified. They will be invited to participate in the study protocol, and will sign informed consent during the medical visit. If they accept, they will be explained that they can withdraw from the study whenever they wish. The initial medical interview will then be conducted to assess the sociodemographic, clinical, and comorbid characteristics of the PWH, eating habits, exercise, alcoholism and smoking; in addition, anthropometric measurements will be taken with the 4-point bioimpedance equipment (FitScan segmental body composition monitor C-545F), which expresses weight in kilograms, water in %, muscle in kg, bone in kg, fat in %; waist and hip will be recorded on the data collection sheet. The principal or associate investigator will take measurements in centimeters, in addition to vital signs such as blood pressure, heart rate, respiratory rate, oxygen saturation, prior to entering the study. In addition, in that first consultation, the following will be assessed: Glucose, creatinine, lipid profile, liver function test, complete blood count, viral load, CD4+, hepatitis B virus serology, hepatitis C virus serology, and VDRL. Randomization will be performed using the MEDSHARING digital system for each of the two arms, consisting of DTG/3TC or BIC/FTC/TAF. Follow-up appointments will be held at 4, 12, 24, 36, 48, 72, 96, 120, 144 weeks after randomization with further laboratory studies at baseline and at 4, 12, 24, 36, 48, 72, 96, 120, 144 week. Glucose, creatinine, lipid profile, liver profile, complete blood count, adverse events by organ and system, and DAIDS scale will be assessed at 4, 12, 24, 48, 72, 96, 120, 144 weeks after randomization; HIV-1 viral load and CD4+ count will be assessed at 12, 24, 48, 72, 96, 120 and 144 weeks after study entry.Also, Neuropsychiatric disorders will be assessed with scales for depression, anxiety and insomnia: Hospital Anxiety and Depression Scale (HADS-D, HADS-A), Insomnia Severity Index (ISI), Patient Health Questionnaire (PHQ-9) prior to entering the protocol, at 4, 12, 24, 48 72, 96, 120 and 144 weeks after randomization; satisfaction with the treatment and distress associated with it will be assessed using the HIVTSQ and HIVSDM scales will be measured after 4, 12, 24, 48, 72, 96, 129, 144 weeks after randomization.

Sampling and Sample Calculation Sampling will be simple random sampling (1:1), with participation in the study offered to all ART-naive PWH who meet the selection criteria and sign the informed consent form. For this study, the target sample size was 103 participants per treatment group, based on 80% power, an α level of 2.5%, a non-inferiority margin of -10% for virologic efficacy (non-inferiority is established if the lower bound of the 2-sided 95% CI for the difference in response is greater than -10% between the two groups), and an assumed true response of 93% at week 48 for both treatment groups. Considering a 20% attrition rate, a total of 124 patients (62 PWH in each arm) are planned for enrollment.

Statistical Analysis Data will be described using proportions, frequencies, or percentages for categorical variables and using mean and standard deviation or median and percentile, according to their Kolmogorov-Smirnov distribution, for quantitative variables.

The incidence rate of metabolic syndrome, significant weight gain, dyslipidemia, overweight/obesity, and dyslipidemia will be calculated.

The Chi-square test or Fisher's exact test will be used to determine the relative risk of developing metabolic changes with the factors analyzed.

In the bivariate analysis, the paired T test or Wilcoxon paired rank sum test will be used to assess statistical significance at baseline at 48 weeks of follow-up. Statistical significance will be considered as a p value ≤0.05 with a 95% CI. For measurements at baseline, 24, and 48 weeks, the Friedman test or ANOVA will be used, depending on the type of variable.

The differences between the two groups with respect to metabolic changes and the variables studied will be determined using the Student t test or the Mann-Whitney U test, as appropriate.

In the multivariate analysis, binary logistic regression will be performed on all variables that were statistically significant in the bivariate analysis to determine the independence of the variables. Statistical analysis will be performed using SPSS (IBM) version 29.0.2 for the Mac OS Ventura operating system.

This protocol will be submitted to the institution's Ethics and Scientific Research Committee for authorization in accordance with international guidelines, including the Declaration of Helsinki, the international guidelines for biomedical ETHICS This protocol will be submitted to the institution's Ethics and Scientific Research Committee for authorization in accordance with international guidelines, including the Declaration of Helsinki, the international guidelines for biomedical research involving human subjects, from the Council for International Organizations of Medical Sciences (CIOMS) and the World Health Organization (WHO), as well as the Guidelines for Good Clinical Practice of the International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH).

Confidentiality of results: This protocol will be conducted in accordance with the guidelines of local hospital authorities and based on legal structures that do not overrule the Mexican Social Security Institute. All procedures will be in accordance with the provisions of the Regulations of the General Health Law on Clinical Research. Likewise, this study will comply with the Organic Law based on public statistics, which guarantees that those providing information will be included, with the exception of identifying individuals. A unique folio number will be established on the data collection sheet, where the study will be entered, and all personal data of participants will be removed.

In the Regulations of the General Health Law on Health Research, Article 17, the randomization process considers a risk greater than minimal.

The regimens that will be used in the treatment of ART-naive PWH are recommended by national and international guidelines, so candidate PWH will receive the best treatment option in Mexico.

The probability of complications corresponding to the adverse events inherent to each treatment regimen corresponds to the adverse events inherent to each treatment regimen. Furthermore, laboratory tests are usually requested for monitoring PWH who begin ART in IMSS units. Obtaining laboratory studies may be associated with adverse events related to venipuncture and the use of sterile materials, such as pain, bruising, vascular injuries, nerve injuries, or infections. If any of these occur, participants will be instructed to seek evaluation and will receive medical treatment if necessary.

03

Conditions studied

  • HIV Infection
  • Metabolic Syndrome
  • Antiretroviral Treatment

Keywords

  • HIV
  • dual-therapy
  • BIC/TAF/FTC
  • DTG/3TC
  • metabolic syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥18 years of age , diagnosed with , and naive to antiretroviral treatment.
  2. HIV-1 RNA quantified by RT-PCR ≥500 and less than 500,000 copies/mL.
  3. No history of PrEP or PEP use.
  4. Estimated ≥30 mL/min/1.73 m2 SC.
  5. No current or planned use of medications associated with significant weight changes during the study period.
  6. Be a beneficiary of the Mexican Social Security Institute treated at the Infectious Diseases Hospital, La Raza National Medical Center.
  7. Willingness of the participant to give consent.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of metabolic syndrome.
  2. uncontrolled diabetes
  3. to the use of INSTIs.
  4. Known mutations in any of the components of either regimen (second-generation INSTIs, 3TC/FTC, or TAF).
  5. Co-medications that have potential interactions with any of the components of the antiretroviral regimens.
  6. Coinfection with or virus.
  7. High cardiovascular risk (Framinham >20% or AHA/ACC >7.5%).
  8. Use of recreational drugs with anorexigenic potential (crystal, methamphetamines, cocaine) 60 days prior to randomization.
  9. Hospitalization for acute or severe illness 30 days prior to randomization
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Active comparator
    BIC/TAF/FTC

    Bictegravir/ tenofovir alafenamide/ emtricitabine 50/ 25/ 200 mg. It is the usual therapy, consisting of 3 drugs in a single tablet, based on an integrase inhibitor, and 2 nucleoside analogues.

    Drug: Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)

  • Experimental
    DTG/3TC

    Dolutegravir/lamivudine 50/300 mg. 2-drug therapy in 1 tablet, co-formulated with 1 integrase inhibitor and 1 nucleoside analogue

    Drug: DTG/3TC

Interventions

06

What researchers measure

Primary outcomes

  1. To determine the effectiveness of Dolutegravir/Lamivudine compared with Bictegravir/Tenofovir Alafenamide/Emtricitabine in ART-naive people with HIV at 144 weeks of treatment.

    -Effectiveness: Number of participants with viral load measurement (HIV-1 RNA) \<50 copies/mL at 144 weeks of follow-up for PWH treated with DTG/3TC or BIC/FTC/TAF, expressed in proportions.

    Time frame: 144 weeks of follow-up with interim analysis at 48 and 96 weeks

  2. To determine the safety of Dolutegravir/Lamivudine compared with Bictegravir/Tenofovir Alafenamide/Emtricitabine in ART-naive people living with HIV at 144 weeks of treatment.

    Number of participants with treatment-related adverse events as assessed of serious adverse events (WHO grade 3 or 4) for PWH treated with DTG/3TC or BIC/FTC/TAF at 144 weeks, expressed in proportions of new cases.

    Time frame: 144 weeks, with intermediate measurements at 48 and 96 weeks

  3. To determine the tolerability of Dolutegravir/Lamivudine compared with Bictegravir/Tenofovir Alafenamide/Emtricitabine in ART-naive people living with HIV at 144 weeks of treatment.

    Number of participants with secondary events associated with ART for PWH treated with DTG/3TC or BIC/FTC/TAF at 144 weeks expressed in proportions and percentages, graded from 1 to 4 according to DAIDS: Grade I: mild Grade II: moderate Grade III: severe Grade IV: life-threatening

    Time frame: 144 weeks, intermediate measurements at 48 and 96 weeks

Secondary outcomes

  1. Metabolic syndrome incidence in DTG/3TC vs BIC/TAF/FTC at 144 weeks

    To determine the incidence of metabolic syndrome in ART-naive PWH initiating a regimen containing DTG/3TC compared with BIC/FTC/TAF after 48 weeks of follow-up, determined by the ATPIII criteria.

    Time frame: 144 weeks, interim analyses at 48 and 96 weeks

  2. To evaluate changes in cardiovascular risk based on AHA/ACC score in ART-naive PWH starting a regimen with DTG/3TC compared with BIC/FTC/TAF after 144 weeks of follow-up.

    To evaluate and compare changes in cardiovascular risk based on the ASCVD (Atherosclerotic Cardiovascular Disease) 2013 Risk Calculator from American College of Cardiology (ACC) and American Heart Association in ART-naive PWH initiating DTG/3TC regimen compared with BIC/FTC/TAF after 144 weeks of follow-up. This is classified in percentage as follows: High cardiovascular risk: ≥20% Borderline cardiovascular risk: ≥5%-\<7.5% Low cardiovascular risk: \<5% The score is directly proportional to the risk, and determines the 10-year risk of ASCVD, for example: myocardial infarction, stroke, or death due to coronary heart disease or stroke

    Time frame: 144 weeks, with interim analyses at 48 and 96 weeks

  3. To determine the incidence of overweight/obesity in ART-naive PWH initiating a DTG/3TC regimen compared with BIC/FTC/TAF after 144 weeks of follow-up.

    To determine incidence of overweight/obesity by body mass index (BMI) ART-naive PWH initiating a DTG/3TC regimen compared with BIC/FTC/TAF after 144 weeks of follow-up.

    Time frame: 144 weeks, with interim analyses at 48 and 96 weeks

  4. To determine significant weight changes in ART-naive PWH initiating a DTG/3TC regimen compared with BIC/FTC/TAF after 144 weeks of follow-up.

    To determine significant weight changes (\>10% body weight gain) in proportions and percentages in ART-naive PWH initiating a DTG/3TC regimen compared with BIC/FTC/TAF after 144 weeks of follow-up.

    Time frame: 144 weeks, with interim analyses at 48 and 96 weeks

  5. To determine the incidence of virologic failure in ART-naive in PWH treated with DTG/3TC compared with BIC/TAF/FTC at 144 weeks of follow-up

    The incidence of virological failure is those new cases of virological failure, defined in Mexico as 2 consecutive determinations in a period of 6 months with HIV-1 viral load \>200 copies/mL

    Time frame: 144 weeks, with intermediate measurements at 48 and 96 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. PubMed 28867497 ↗
  • Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials: Erratum. J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):e21. doi: 10.1097/QAI.0000000000002394. PubMed 32530908 ↗
  • Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. PubMed 30420123 ↗
  • Kelly SG, Nyaku AN, Taiwo BO. Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere? Drugs. 2016 Apr;76(5):523-31. doi: 10.1007/s40265-016-0553-8. PubMed 26886135 ↗

Individual participant data

Plan to share: No — Participant data are confidential and may be requested from the principal investigator.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 78 non-industry phase 4 interventional studies under HIV Infections, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 45. This study's planned 20 months is below that.

Counting every sponsor, half of 91 studies reached it within 35 months; a quarter within 23 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2025
First posted
Jun 22, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2028
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07031063
Responsible party
José Antonio Mata Marín (Dr. José Antonio Mata Marín, Instituto Mexicano del Seguro Social) — Principal investigator
First posted
Jun 22, 2025
Start date
Apr 1, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Jun 26, 2025

Study contacts

José A Mata, M.Sc.
Contact
jamatamarin@gmail.com
525530379053
Ana L Cano, Posgraduate
Contact
ana.knodiaz@gmail.com
522291243665
José A Mata, Master degree
principal investigator · Instituto Mexicano del Seguro Social

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dolutegravir · Lamivudine

Start the discussion